Philip Parente
Papers
1
Total Citations
25
H-Index
1
About
Philip Parente is a leading clinical oncologist whose research focuses on improving outcomes for patients with genitourinary malignancies, particularly metastatic castration-resistant prostate cancer (mCRPC). His most cited work, a final pooled analysis of the cabazitaxel compassionate use and early access programmes, provides critical real-world evidence on the efficacy and safety of this taxane chemotherapy in heavily pretreated mCRPC patients. This landmark study, which has garnered 25 citations, demonstrated that cabazitaxel remains a viable and manageable treatment option beyond clinical trial settings, offering valuable guidance for clinicians navigating late-stage disease management. Parente’s contributions are instrumental in bridging the gap between controlled trials and everyday clinical practice, ensuring that novel therapies translate into tangible benefits for patients. His collaborative efforts in large-scale, multinational analyses underscore his commitment to evidence-based oncology and have shaped treatment paradigms for advanced prostate cancer. Through his rigorous evaluation of therapeutic outcomes, Parente continues to influence how oncologists approach chemotherapeutic sequencing, making a lasting impact on the field of urological oncology.
Research Focus
Key Achievements
Top Papers
- 1